Setmelanotide - Rhythm Pharmaceuticals

Drug Profile

Setmelanotide - Rhythm Pharmaceuticals

Alternative Names: BIM-22493; CAM 4072; RM-493

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ipsen
  • Developer Charite - Universitatsmedizin Berlin; Ipsen; Rhythm
  • Class Amides; Antihyperglycaemics; Cyclic peptides; Cysteines; Disulfides; Obesity therapies
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Obesity
  • Phase I Diabetes mellitus

Most Recent Events

  • 31 Oct 2017 Efficacy and adverse event data from a phase II trial in Obesity released by Rhythm Pharmaceuticals
  • 04 Sep 2017 Rhythm Pharmaceuticals initiates an expanded access for Lipodystrophy and Hypertriglyceridaemia in USA (NCT03262610)
  • 27 Jun 2017 Rhythm initiates enrolment in a phase Ia trial for Obesity (In volunteers) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top